Incidental finding of endolymphatic stromal myosis during luteinizing hormone releasing hormone agonist therapy for suspected benign uterine myomata. A case report.

Abstract

A 39-year-old woman with an enlarging myomatous uterus underwent a three-month course of luteinizing hormone releasing hormone (LHRH) agonist treatment. Despite a 50% reduction in uterine size, pathologic examination after uncomplicated hysterectomy revealed a low-grade endometrial stromal sarcoma. As the use of LHRH agonists for myoma reduction increases, delay in the diagnosis of sarcomatous disease will become more widespread. With current available diagnostic modalities, differentiation between sarcomatous and myomatous growth within the uterus is difficult. The possibility of delay in the diagnosis of unsuspected sarcoma when using LHRH agonists is an inherent and apparently unavoidable complication in some cases.

• Authors: S Smith, M Cooper, J S Schinfeld
• Journal: The Journal of reproductive medicine (J Reprod Med) Vol. 37 Issue 12 Pg. 980-2 (Dec 1992) ISSN: 0024-7758 [Print] United States
• PMID: 1287209 (Publication Type: Case Reports, Journal Article)

Chemical References

• Nafarelin

Topics

• Adult
• Diagnosis, Differential
• Diagnostic Errors
• Female
• Humans
• Leiomyoma (diagnosis, drug therapy, surgery)
• Nafarelin (therapeutic use)
• Sarcoma (diagnosis, pathology)
• Uterine Neoplasms (diagnosis, drug therapy, surgery)